Table 1.
Recommendation for HIV testing and reporting of association with HIV, stratified by type of guideline
| Number of guidelines identified (% of total) | Association with HIV reported n (%) | HIV testing recommended n (%) | P‐value for between‐group difference in HIV testing recommendation | ||||
|---|---|---|---|---|---|---|---|
| All guidelines | 78 | (100) | 41 | (53) | 30 | (38) | |
| AIDS‐defining conditions | 17 | (21) | 9 | (53) | 6 | (35) | 1.0 |
| Indicator conditions | 61 | (78) | 32 | (52) | 24 | (39) | |
| Source of guideline | |||||||
| NICE | 12 | (15) | 7 | (58) | 3 | (25) | 0.021 |
| NICE Clinical Knowledge Summaries | 29 | (37) | 18 | (62) | 11 | (38) | |
| SIGN | 8 | (10) | 0 | (0) | 0 | (0) | |
| Specialty society guidelines | 29 | (37) | 16 | (55) | 16 | (55) | |
| Guidelines for eight key indicator conditionsa | |||||||
| Total | 34 | (100) | 27 | (79) | 20 | (59) | 0.002b |
| Sexually transmitted infections | 13 | (38) | 13 | (100) | 7 | (54) | 0.20 |
| Malignancy or lymphoma | 3 | (9) | 3 | (100) | 3 | (100) | |
| Cervical or anal cancer/dysplasia | 5 | (15) | 1 | (20) | 1 | (20) | |
| Herpes zoster | 1 | (3) | 0 | (0) | 0 | (0) | |
| Hepatitis B or C virus (acute or chronic) | 6 | (18) | 4 | (67) | 4 | (67) | |
| Mononucleosis‐like illness | 2 | (6) | 2 | (100) | 1 | (50) | |
| Unexplained leucocytopaenia, thrombocytopaenia (>4 weeks) | 3 | (9) | 3 | (100) | 3 | (100) | |
| Seborrhoeic dermatitis/exanthema | 1 | (3) | 1 | (100) | 1 | (100) | |
NICE, National Institute of Clinical Excellence; SIGN, Scottish Intercollegiate Guidance Network.
a
The eight key indicator conditions were tested as part of the HIDES 1 study and were associated with a prevalence of undiagnosed HIV infection of >0.1%.
b
The P‐value refers to the comparison between guidelines for the eight key indicator conditions and remaining guidelines.